Background: The venoms of predators have been an excellent source of diverse highly specific peptides targeting ion channels. Here we describe the first known peptide antagonist of the nociceptor ion channel transient receptor potential ankyrin 1 (TRPA1). Results: We constructed a recombinant cDNA library encoding w100 diverse GPI-anchored peptide toxins (t-toxins) derived from spider venoms and screened this library by coexpression in Xenopus oocytes with TRPA1. This screen resulted in identification of protoxin-I (ProTx-I), a 35-residue peptide from the venom of the Peruvian green-velvet tarantula, Thrixopelma pruriens, as the first known high-affinity peptide TRPA1 antagonist. ProTx-I was previously identified as an antagonist of voltage-gated sodium (Na V ) channels. We constructed a t-toxin library of ProTx-I alanine-scanning mutants and screened this library against Na V 1.2 and TRPA1. This revealed distinct partially overlapping surfaces of ProTx-I by which it binds to these two ion channels. Importantly, this mutagenesis yielded two novel ProTx-I variants that are only active against either TRPA1or Na V 1.2. By testing its activity against chimeric channels, we identified the extracellular loops of the TRPA1 S1-S4 gating domain as the ProTx-I binding site. Conclusions: These studies establish our approach, which we term ''toxineering,'' as a generally applicable method for isolation of novel ion channel modifiers and design of ion channel modifiers with altered specificity. They also suggest that ProTx-I will be a valuable pharmacological reagent for addressing biophysical mechanisms of TRPA1 gating and the
Introduction
Transient receptor potential (TRP) channels are diverse sixtransmembrane domain (6-TM) cation channels that are related to, and share, the transmembrane topology and functional domain structure of the tetrameric voltage-gated ion channels. The first four transmembrane domains (S1-S4) form the gating domain, while the S5 and S6 segments span the re-entrant pore loop to form the selectivity filter and ion conducting pore [1, 2] . TRP channels are involved in almost all aspects of sensory transduction, including vision, olfaction, mechanosensation, thermosensation, and physiological/pathological pain sensing [3] . Several dozen TRP channels have been identified and are classified into six subfamilies, including the TRP ankyrin family (TRPA), with varying degrees of sequence similarity and permeability to cations [2] . TRPA1 is the only member of the ankyrin subfamily so far identified in mammals, and it contains at least 14 ankyrin repeats in the N-terminal intracellular domain [4] . TRPA1 is activated by a variety of chemical compounds, such as allyl isothiocyanate in mustard oil (MO), allicin in garlic and onion [5, 6] , and synthetic drugs such as clotrimazole [7] , chlorpromazine [8] , and clioquinol [9] . TRPA1 can also be activated by endogenous metabolic products and oxidative stress-derived substances and sensitized through G proteincoupled receptors (GPCRs) [10] , cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) [11] , and protease activated receptor 2 (PAR2) [12] signaling pathways. In mice, TRPA1 is highly expressed in unmyelinated and thinly myelinated sensory neurons of dorsal root ganglion (DRG), nodose ganglion (NG), and trigeminal ganglion (TG) neurons [4, 13] , and expression in the urethra, urinary bladder, prostate gland, and arteries has also been observed [14] [15] [16] [17] [18] . TRPA1 is coexpressed with TRPV1 in many small-diameter nociceptor sensory neurons that contain both substance P and calcitonin gene-related peptide [4] . TRPA1 knockout mice exhibit pronounced deficits in bradykinin-evoked nociceptor excitation and pain hypersensitivity [10] . TRPA1 is upregulated in inflammatory injury and neuropathic pain, and perturbation of TRPA1 activity can protect against cold-induced hyperalgesia [19] [20] [21] [22] [23] [24] . The central role for TRPA1 in pain sensation is starkly highlighted by a gain-of-function TRPA1 mutation in human patients suffering from familial episodic pain syndrome, in which patients suffer debilitating pain on fasting and physical stress [25] .
The importance of TRPA1 in pain signaling makes it a potential target for the treatment of pathological pain [26] . While some small-molecule TRPA1 antagonists have been identified [26, 27] , no peptide antagonists of TRPA1 have been reported. The venoms of predators, such as spiders, scorpions, cone snails, sea anemones, and snakes, have been an excellent source of peptide diversity for drug discovery and as pharmacological tools for elucidating the structure, function, and physiological properties of ion channels [28, 29] . For example, hanatoxin, a 35-residue peptide from Chilean rose tarantula venom, has been invaluable for probing the structure and function of K + channels [30, 31] . a-Bungarotoxin, a 74-residue peptide from elapid snakes, has been an essential tool in the study of nicotinic acetylcholine receptors [32] . A peptide toxin from cone snail targeting Ca V 2.2 channels has already been developed into a Food and Drug Administration (FDA)-approved treatment for intractable pain in human patients [33] .
A key issue in ion channel toxin biology has been the mining of this great pharmacological diversity-e.g., spiders alone are estimated to collectively contain millions of distinct peptide toxins in their venoms [28] -to identify toxins with high affinity for particular ion channel targets. Here we report the development and validation of a novel peptide toxin screening platform utilizing the previously described ''tethered-toxin'' (t-toxin) recombinant expression method [34, 35] and its use to identify the first known peptide antagonist of TRPA1. We constructed a cDNA library containing w100 t-toxins derived from published and unpublished spider toxin sequences (Table S1 available online), each encoded in glycosyl phosphatidyl inositol (GPI)-anchored membrane-tethered form. By screening this library through functional coexpression with cloned ion channel subunits, we identified protoxin-I (ProTx-I), a 35-residue peptide from the venom of the Peruvian greenvelvet tarantula, Thrixopelma pruriens, previously identified as an antagonist of voltage-gated sodium (Na V ) channels [36, 37] , as a high-affinity TRPA1 antagonist. We found that ProTx-I inhibits both Na V and TRPA1 by binding to the S1-S4 gating domains of these distantly related 6-TM channels. These studies establish screening of t-toxin libraries of native and mutated toxins, which we term ''toxineering,'' as a generally applicable method for isolation of novel ion channel modifiers and for design of ion channel modifiers with altered target selectivity. They also suggest that ProTx-I will be a valuable pharmacological reagent for addressing the biophysical mechanisms of TRPA1 gating and the physiology and pathophysiology of TRPA1 function in nociceptors, as well as for potential clinical application in the context of pain and inflammation.
Results

Screen of a Recombinant Membrane-Tethered Spider Toxin Library for TRPA1 Antagonists
It has recently been demonstrated that peptide ion channel toxins from venomous predators can be heterologously expressed as fusion proteins covalently tethered to GPI anchors inserted in the extracellular leaflet of the plasma membrane [34, 35] . Various cysteine-rich toxins from snakes, cone snails, and spiders have been expressed in t-toxin form, where they exhibit identical pharmacological specificity to the native toxins [34, 35] . We generated a t-toxin library of approximately 100 cysteine-rich toxin sequences, a combination of both previously published and unpublished sequences from an ongoing large-scale spider venom-gland transcriptomics effort at the University of Queensland. Toxin sequences were cloned into a t-toxin backbone plasmid comprising a trypsin secretory signal sequence, glycine-asparagine repeat linker with embedded c-Myc epitope tag, and GPI targeting sequence from the mammalian Lynx1 peptide, a modulator of the nicotinic acetylcholine receptor (nAChR) ( Figure 1A ) [34, 35] . The plasmid contains an upstream bacteriophage RNA polymerase promoter for cRNA synthesis. cRNAs of each of the t-toxins were synthesized in vitro and randomly combined into 14 pools of six or seven toxins each. Xenopus oocytes were coinjected with each t-toxin pool and TRPA1 cRNA ( Figure 1B) . One pool of toxins significantly suppressed the inward TRPA1 current induced by 100 mM mustard oil (MO) ( Figure S1A ). Each t-toxin in the positive pool was then tested individually by coinjection with TRPA1 cRNA ( Figure S1B ). This enabled identification of ProTx-I, a spider toxin previously shown to block several different voltage-gated ion channels [36] [37] [38] , as a TRPA1 antagonist ( Figure 1C ).
Soluble ProTx-I Is a High-Affinity TRPA1 Antagonist In order to confirm that the observed activity of t-ProTx-I against TRPA1 is not an artifactual consequence of its GPI membrane-tethered configuration, we measured the activity of chemically synthesized soluble ProTx-I against TRPA1. We expressed TRPA1 in HEK293 cells and measured MOinduced currents with perforated whole-cell patch-clamp electrophysiology. Inhibitory activity was defined as I toxin / I RR, where I toxin is the current inhibited by bath-applied ProTx-I and I RR is the current inhibited by ruthenium red (RR), a nonspecific TRP channel pore blocker. As shown in Figures  2A and 2B, 1 mM soluble ProTx-I inhibits MO-induced currents by 63%. Dose-response analysis of TRPA1 antagonism by soluble ProTx-1 reveals maximum inhibition of 90.9% 6 2.3%, and IC 50 of 389 6 77 nM ( Figure 2C ). The binding of ProTx-I to TRPA1 is reversible, as inhibition is completely relieved by washout ( Figure 2B ). Antagonism of TRPA1 by soluble ProTx-I was further confirmed by imaging of Ca 2+ influx, as shown in Figure S3A . We also tested the effect of soluble ProTx-I on TRPV1, a thermosensitive and chemosensitive TRP channel that plays an important role in pain signaling [39] . ProTx-I (1 mM) has no significant effect on TRPV1 currents (ANOVA, p = 0.39; Figure S3B ). These results confirm that recombinant expression as a t-toxin faithfully recapitulates the pharmacological activity of native ProTx-I. MO, like endogenous tissue stress and injury signals such as 4-hydroxy-nonenal (produced during oxidative stress), hydrogen peroxide, hydroxyl radicals, and hypochlorite (produced by activated neutrophils), activates TRPA1 via covalent modification of the cysteine-rich intracellular C terminus [40] [41] [42] [43] [44] . We also tested whether ProTx-I inhibits TRPA1 currents activated by allosteric modulators that interact with transmembrane domains, and not the intracellular C terminus, such as menthol and carvacrol [41, 45, 46] . ProTx-I inhibits the Ca 2+ influx through TRPA1 activated with either menthol or carvacrol (Figures S3C and S3D ). We also confirmed that ProTx-I inhibits Ca 2+ influx through native TRPA1 in cultured mouse dorsal root ganglion nociceptors ( Figure S3E ). The relatively modest magnitude of the effect on mouse nociceptor TRPA1 is explained by the weaker potency of ProTx-I against cloned mouse TRPA1 versus human TRPA1, with 3 mM ProTx-I having a smaller effect on mouse TRPA1 than 1 mM ProTx-I on human TRPA1 ( Figure S3F ).
t-ProTx-I Inhibits Mammalian and Insect Voltage-Gated Na + Channels ProTx-I inhibits some subtypes of voltage-gated Na + , Ca 2+ , and K + channels [38, 47] . To test whether membrane-tethered t-ProTx-I behaves similarly, we coexpressed t-ProTx-I with Na V channels or with voltage-independent inward-rectifier Kir4.1, which lacks a voltage-sensor domain (VSD) and only possesses the S5-S6 pore-forming domain. When coexpressed with Na V 1.2, t-ProTx-I inhibits w60% of the inward Na + current ( Figures 3A and 3B ). When coexpressed with the Drosophila para Na V channel, t-ProTx-I inhibits inward Na + current completely ( Figures 3C and 3D ). This suggests that ProTx-I has higher affinity for insect than mammalian Na + channels, presumably because this toxin has been tuned during the course of spider-venom evolution to target the voltage-gated channels of insect prey. Consistent with the potency of t-ProTx-I at inhibiting para currents, bath-applied soluble ProTx-I completely silences action potential firing in a Drosophila whole-brain electrophysiological preparation ( Figure S2 ). In contrast, t-ProTx-I has no effect on kinetics or amplitude of inward-rectifier K + current ( Figures 3E and 3F ). This leads to the hypothesis that ProTx-I binds to the S1-S4 gating domain that is common to ion channels with six TM domains (TRP channels and voltage-gated channels), but lacking in the inward-rectifier K + channels that only possess the two pore-spanning TM domains.
Voltage-and Time-Dependent Unbinding of ProTx-I from Voltage-Gated Na + Channel Binding of a-scorpion toxins and ProTx-II, another cysteinerich toxin from the Peruvian green-velvet tarantula, to the VSD of Na V channels can be reversed by sustained membrane depolarization [48] [49] [50] . This supports a model in which the toxins dissociate more rapidly from the channel in the activated state than in the closed state, thereby stabilizing the closed conformation [51] . To test whether ProTx-I inhibits Na V channels by a similar mechanism, we imposed depolarizing prepulses (+100 mV) of varying duration, followed by 80 ms See also Figure S1 and Table S1 .
at the hyperpolarized holding potential (2100 mV) to allow recovery from fast inactivation, and then a test pulse to +10 mV ( Figure 4A ). As shown in Figures 4B and 4C , depolarizing prepulses cause unbinding of t-ProTx-I from para coexpressed in Xenopus oocytes, with the amplitude of the unblocked current increasing with the duration of the prepulse. Bath-applied ProTx-I (200 nM) exhibits identical unbinding kinetics, with complete reversal by a 1 s depolarizing prepulse ( Figures 4D and 4E ). These results indicate that ProTx-I blocks voltage-gated ion channel currents by dissociating more slowly from, and thereby stabilizing, the closed conformation of the activation voltage gate. Moreover, they establish that GPI tethering has no effect on the mechanism of channel binding by ProTx-I.
Identification of Channel Binding Surfaces of ProTx-I by Alanine-Scanning of t-ProTx-I
In order to identify the surface of ProTx-I that mediates its binding to voltage-gated channels and TRPA1, we generated a library of alanine-scanning mutants of t-ProTx-I, with each non-Cys and non-Ala residue mutated individually to Ala. This alanine-scanning approach has previously been used with chemically synthesized and recombinantly expressed peptide toxins to identify target binding surfaces [52] [53] [54] [55] . We screened this library against Na V 1.2 and TRPA1 by coexpression in Xenopus oocytes and measurement with twoelectrode voltage clamp of voltage-or MO-induced currents.
Detailed results of these recordings with statistical comparisons are shown in Figure S4 . Importantly, none of the alanine mutants exhibit reduced t-ProTx-I surface expression, thus ruling out expression or trafficking defects as causes of altered activity ( Figure S5 ). In order to visualize the target binding surfaces, we mapped each residue whose mutation significantly reduces t-ProTx-I inhibitory activity against TRPA1 or Na V 1.2 to the high-resolution structure of ProTx-I that we determined using nuclear magnetic resonance spectroscopy ( Figure 5 ). Each of the side chains whose mutation to alanine reduces inhibitory activity against either channel are located on the toxin surface, except for Leu19, which is internal, suggesting that the L19A mutation disrupts ProTx-I folding. The TRPA1 binding surface (pharmacophore) comprises five side chains, whereas ten residues make up the pharmacophore for Na V 1.2. Three residues are in common between the two binding surfaces: Ser22, Trp30, and Phe34. Importantly, mutation of particular residues leads to t-ProTx-I variants that are specific inhibitors of either TRPA1 or Na V 1.2, but not the other, such as t-ProTx-I (W5A) and t-ProTx-I (S22A) ( Figure 5D ). Of the six charged residues of ProTx-I, three participate in channel binding-Arg3, Arg23, and Asp 31-but only with Na V 1.2. The involvement of both hydrophobic and charged side chains in the interaction of ProTx-I with Na V 1.2 and the larger binding surface are consistent with the substantially higher affinity of ProTx-I for voltage-gated channels (IC 50 of 30-90 nM [36] ) compared with TRPA1 (389 nM; Figure 2 ). The substantial overlap of the ProTx-I surfaces that bind to TRPA1 and Na V 1.2-three of the five TRPA1-binding side chains are shared between the two pharmacophores-is compatible with the hypothesis that ProTx-I binds to TRPA1 by a similar S1-S4 gating mechanism as it does to voltage-gated channels.
ProTx-I Binding to TRPA1 Involves the S1-S2 Extracellular Loop ProTx-I has been previously shown to bind to chimeric K V 2.1 containing VSD II or VSD IV from rat Na V 1.2 [47] . In combination with the overlapping ProTx-I binding surfaces for Na V 1.2 and TRPA1 ( Figure 5 ) and the mechanism of Na V 1.2 inhibition (Figure 4 ), this suggests that ProTx-I could inhibit TRPA1 by binding to the extracellular face of its S1-S4 gating domain. In order to test this hypothesis, we attempted to confer greater sensitivity to ProTx-I on a less-sensitive 6-TM channel by transplant of the TRPA1 S1-S2 extracellular loop. As shown in Figure 6 , both soluble and membrane-tethered ProTx-I only slightly inhibit the inward currents of NaChBac bacterial Na V channel expressed in oocytes [56] . In contrast, chimeric NaChBac with the S1-S2 linker of TRPA1 is substantially inhibited by ProTx-I, either membrane tethered or soluble (Figure 6 ). Similar to NaChBac expressed in Xenopus oocytes, bath-applied soluble ProTx-I suppresses the currents of the chimera expressed in HEK293 cells substantially more than wild-type NaChBac ( Figures 6E and 6F) . Interestingly, the S1-S2 loop chimera NaChBac channel expressed in oocytes appears more sensitive to ProTx-I than when expressed in HEK293 cells, as 200 nM ProTx-I suppresses oocyte currents more than 3 mM ProTx-I suppresses HEK293 currents. This greater antagonism of ProTx-I for the S1-S2 loop chimera NaChBac supports the hypothesis that it inhibits TRPA1 by the same mechanism as voltage-gated channels: slower dissociation and stabilization of the closed conformation of the S1-S4 gating domain.
Discussion
We have developed and validated a generally applicable platform for toxin discovery and functional analysis and have identified ProTx-I as the first known peptide TRPA1 antagonist by using this novel recombinant t-toxin library screening approach. ProTx-I will be a valuable pharmacological reagent for addressing the biophysical mechanisms of TRPA1 gating and the physiology and pathophysiology of TRPA1 function in nociceptors, as well as for potential clinical application in the context of pain and inflammation. We also generated and screened a t-toxin library of alanine-scanning mutants of ProTx-I and thereby identified the partially overlapping surfaces of ProTx-I by which it binds to TRPA1 and Na V 1.2 ( Figure 5 ). Importantly, this mutagenesis has yielded novel ProTx-I variants that are only active against either TRPA1 (W5A) or Na V 1.2 (S22A) ( Figure 5D ). On the basis of these identified binding surfaces, further directed mutagenesis and screening of tethered ProTx-I libraries should be a feasible means to obtain variants with even higher affinity and specificity for TRPA1.
Comparison of the Na V 1.2 binding surface of ProTx-I that we identified here with the Na V 1.5 binding surface of ProTx-II previously identified by chemical synthesis of alanine mutants [52] reveals that hydrophobic and electrostatic interactions are important for both ProTx-I and ProTx-II binding to voltage-gated Na + channels. All tryptophans in both toxins contribute to interactions with Na V channels ( Figure S6 ). For example, Trp5, Trp27, and Trp30, whose mutation to alanine completely abolishes ProTx-I inhibition of Na V 1.2, are conserved in ProTx-II, and their mutation to alanine reduces affinity of ProTx-II for Na V 1.5 [52] . Interestingly, with the exception of Trp27, all residues that are important for ProTx-I binding toTRPA1 are not conserved in ProTx-II, which may explain why ProTx-I, but not ProTx-II, binds to and inhibits TRPA1 (t-ProTx-II was in the same screening pool as t-ProTx-I and when subscreened on its own had no activity against TRPA1), despite the fact that both toxins inhibit Na V channels [36, 37, 52] .
We also compared our ProTx-I alanine-scanning results with those obtained for the related toxin SGTx1 obtained by chemical synthesis of alanine mutants. SGTx1, isolated from the venom of the African featherleg baboon spider Stromatopelma calceatum griseipes, inhibits the K V 2.1 voltage-gated K + channel by binding to residues in the S3b and S4 helices of the VSD [55] . ProTx-I and SGTx1 have roughly 50% sequence identity (A) Voltage-clamp protocol starts with depolarizing prepulse step to +100 mV of varying duration ranging from 0 to 1,000 ms, 80 ms return to holding potential of 2100 mV to allow recovery from inactivation, followed by a depolarizing test pulse to 210 mV to activate the channel. (B) Inward currents recorded from a representative oocyte coexpressing para and t-ProTx-I increase in amplitude as the duration of the depolarizing prepulse increases.
(C) Bar graph shows the dependence of peak current during the test pulse on the duration of the prepulse. Test pulse currents are normalized to that for the 1,000 ms prepulse. Error bars indicate the mean 6 SEM. (D) Inward currents as in (B), but for an oocyte expressing only para and in the presence of w200 nM bath-applied soluble ProTx-I. (E) Bar graph as in (C) for oocytes expressing only para and in the presence of w200 nM bath-applied soluble ProTx-I. Error bars indicate the mean 6 SEM. . (C) Binding surfaces for both TRPA1 and Na V 1.2 are mapped onto the ProTx-I structure. Orange indicates amino residues involved in binding toTRPA1, red indicates amino acid residues involved in binding to Na V 1.2, and green indicates amino acid residues involved in binding to both ion channels. (D) Representative two-electrode voltage-clamp recordings of Xenopus oocytes coexpressing either Na V 1.2 or TRPA1 with negative-control t-toxin (t-PLTX for Na V 1.2 and t-d-ACTX-Hv1a for TRPA1), wild-type t-ProTx-I, or the indicated alanine mutants of t-ProTx-I. t-ProTx-I (W5A) is strongly active against TRPA1, but has very little activity against Na V 1.2. Conversely, t-ProTx-I (S22A) is strongly active against Na V 1.2, but has very little activity against TRPA1. See also Figures S4-S6 and Table S5 . (A) When coexpressed in Xenopus oocytes with a chimera of NaChBac containing the extracellular S1-S2 loop of TRPA1, t-ProTx-I inhibits peak depolarization-induced inward currents by w80% compared with t-L19A, a mutant ProTx-I that fails to inhibit either voltage-gated sodium channels or TRPA1. In contrast, t-ProTx-I has no significant effect on inward currents of wild-type (WT) NaChBac expressed in oocytes. Error bars indicate the mean 6 SEM.
(B) Representative recording of inward currents from an oocyte coexpressing either WT or chimeric NaChBac with either t-ProTx-I or t-L19A.
(C) Bath-applied ProTx-I (w200 nM) suppresses w50% of peak depolarization-induced inward currents of the chimeric NaChBac channel, but only w20% of the WT NaChBac. Error bars indicate the mean 6 SEM.
(D) Representative recordings of inward currents for an oocyte expressing either WT or chimeric NaChBac with or without the presence of bath-applied soluble ProTx-I. (E) ProTx-I (3 mM) inhibits peak depolarization-induced inward currents of chimeric NaChBac by w30%, but only w10% of WT NaChBac expressed in HEK293 cells. Error bars indicate the mean 6 SEM.
(F) Representative recordings of the effects of 3 mM ProTx-I on NaChBac WT and chimeric NaChBac inward currents from HEK293 cells.
( Figure S6 ). Leu19 in ProTx-I, which is buried inside the toxin as shown in Figure 5 and is possibly involved in ProTx-I folding, is conserved in SGTx1. In the solution structure of SGTx1, the aliphatic side chain of Leu19 is also largely buried inside the toxin, resulting in misfolding of the L19A mutant [55] . As shown in Figure 5 , the Na V 1.2 binding surface of ProTx-I involves a hydrophobic protrusion comprising the side chains of Trp5, Trp30, and Val29, surrounded by nonhydrophobic residues except Trp27 and Phe34, including Arg3, Ser22, Arg23, Asp31, and Gly32. The topological disposition of these residues is quite similar to those in the K V 2.1 binding surface of SGTx1 [55] . These comparisons to related toxin-channel binding interactions strongly suggest that screening of alanine-scanning t-toxin libraries faithfully reveals the target binding surfaces of native soluble toxins. It has been reported that ProTx-I shifts Na V channel activation to more depolarized potentials, but has no effects on inactivation [36, 37] . More recently, ProTx-I was shown to bind to chimeric K V 2.1 containing VSD II or VSD IV from rat Na V 1.2 [47] . Here, we found that ProTx-I impedes Na V channel activation by binding to and stabilizing the voltage sensor in its closed conformation (Figure 4 ). Taken together, these data suggest that ProTx-I inhibits Na V 1.2 by binding to one of the VSDs, most likely the extracellular surfaces of VSDs in channel domains II or IV. Furthermore, the partial overlap of the TRPA1 and Na V 1.2 binding surfaces of ProTx-I and the lack of inhibition of 2-TM inward-rectifer Kir4.1 suggest that ProTx-I binds to TRPA1 by a similar S1-S4 gating mechanism as it does to voltage-gated channels. Consistent with this hypothesis, ProTx-I inhibits chimeric NaChBac bacterial channel with the transplanted S1-S2 loop of TRPA1 more potently than wildtype NaChBac (Figure 6 ). However, the extent of ProTx-I inhibition of the chimeric NaChBac is less than of TRPA1 itself, which suggests that ProTx-I binding to TRPA1 also involves other parts of the S1-S4 extracellular surfaces (several other NaChBac chimeras were also generated but failed to produce stable currents). Regardless, these results indicate a common conformational gating mechanism between TRP and voltagegated channels and establish ProTx-I as a valuable tool for further detailed biophysical analysis of TRPA1 gating mechanisms.
Compared to traditional biochemical fractionation approaches, there are several advantages of the toxineering strategy. First, this method allows screening of large numbers of toxins in equimolar fractions, unlike the highly skewed abundances of toxins in native venoms [57] . Less-abundant toxins may be present in too small a quantity in native venom to detect their activity, or their activity may be masked by more abundant ones. Second, toxineering avoids the need for obtaining native venom or chemically synthesized and in vitro folded toxins. Although various cysteine-rich peptide toxins have been successfully generated in large quantities using either chemical synthesis or recombinant expression in bacteria (e.g., [58, 59] ), appropriate conditions for synthesis, expression, and folding of each toxin have to be determined individually due to distinct chemical and structural characteristics, which is expensive and time consuming. Generation of complex t-toxin libraries for screening requires nothing more than diverse toxin sequences-which are now being generated in huge quantities as a result of spider venom-gland transcriptomics efforts [60] and standard gene synthesis methods. This approach is thus amenable to high-throughput scale up. Third, the toxineering approach enables peptide toxin engineering and screening without the need for chemical synthesis and in vitro folding of large numbers of variant peptides. Indeed, based as it is on site-directed mutagenesis of cDNA, it would be straightforward to generate large-scale mutant t-toxin libraries and screen them for variants with improved affinity and/or specificity for desired targets. Toxineering thus provides a functional screening alternative to the recently reported purely bindingbased phage display method [61] .
Experimental Procedures t-Toxin Design and Library Construction
All t-toxin sequences were generated by replacement of the sequence encoding mammalian Lynx1, a toxin-like nicotinic acetylcholine receptor modulator, by the cDNAs of toxins in frame between the secretion signal and the lynx1 hydrophobic sequence for GPI attachment [34, 35] . A flexible linker containing a glycine-asparagine repeat was inserted between the toxin and the hydrophobic sequence for GPI attachment, and a c-Myc epitope tag was introduced in the middle of the linker. t-toxin cDNAs were cloned into the pCS2+ plasmid vector for in vitro transcription of t-toxin cRNA.
Loop NaChBac Chimera Design A chimeric NaChBac channel was generated by substitution of the NaChBac S1-S2 extracellular loop (ETYPRIYADHKWL, residues 43-55, accession number NP_242367 in PubMed) with the S1-S2 extracellular loop of TRPA1 (KPGMAFNSTGIINETSDHSEILDTTNSYLIKT, residues 741-772, accession number O75762 in UniProt).
Two-Electrode Voltage Clamp
The gene constructs for cloning the Drosophila voltage-gated Na + channel a subunit (para) and its auxiliary b subunit (tipE), pGH19-13-5 para [62] and pGH tipE, were from M. Williamson (Rothamsted Research). Capped cRNAs were prepared by restriction enzyme linearization, followed by in vitro transcription reaction with SP6 or T7 RNA polymerase (mMessenger mMachine kit, Ambion). Concentrations of cRNAs were measured by NanoDrop 2000 (Thermo Scientific), and all toxin cRNAs were diluted to 1 mg/ml. cRNAs of toxins and ion channels of interest were mixed at 1:1 ratio (v/v) and injected into the oocytes. For details of standard two-electrode voltage-clamp protocol, see the Supplemental Experimental Procedures.
HEK293 Cell Culture and Electrophysiology
Human embryonic kidney (HEK) 293 cells (ATCC, CRL-1573) were cultured in Dulbecco's modified Eagle's medium (Lonza) supplemented with 10% fetal bovine serum (Lonza), 2 mM L-glutamine, 100 units/ml penicillin, and 100 mg/ml streptomycin. Cells were transfected by lipofectamine (Invitrogen). For details of the standard whole-cell voltage-clamp protocol, see the Supplemental Experimental Procedures.
Statistical Analysis
All quantitative results are presented as mean 6 SEM. Statistical analyses were performed using unpaired Student's t test or ANOVA with paired comparisons with significance being concluded for p < 0.05.
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